Disease · MONDO_0015243

allergic bronchopulmonary aspergillosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. allergic bronchopulmonary aspergillosis. Diseases, record MONDO_0015243. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015243

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: allergic bronchopulmonary aspergillosis; Open Targets
Open Targets ID: MONDO_0015243; Open Targets
Other names: ABPA, Aspergillosis, Allergic Bronchopulmonary, Hinson-Pepys disease, allergic aspergillosis, pulmonary aspergillus disease; Open Targets
Disease Ontology: DOID:13166; Disease Ontology
MeSH: D001229; MeSH
NCI Thesaurus: C84547; NCI Thesaurus
Orphanet: ORPHA:1164; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ITRACONAZOLE	CHEMBL64391	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	2	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	0	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEFLAZACORT	CHEMBL1201891	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
VORICONAZOLE	CHEMBL638	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
IGHE	Immunoglobulin heavy constant epsilon	1	Ig epsilon chain C region inhibitor	Unknown	https://conductscience.org/library/genes/3497	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 2	https://conductscience.org/library/genes/3566	Drugs and targets
IL5RA	Interleukin-5 receptor subunit alpha	1	Interleukin-5 receptor subunit alpha inhibitor	Unknown	https://conductscience.org/library/genes/3568	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Phase 2/3	https://conductscience.org/library/genes/7421	Drugs and targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04442269	Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)	Phase 2	62	2024-08-21	Allergic Bronchopulmonary Aspergillosis	DUPILUMAB	Its record names the disease	ClinicalTrials.gov
NCT06174922	A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis	Phase 3	300		Allergic Bronchopulmonary Aspergillosis	ITRACONAZOLE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT06447402	A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis	Phase 3	196		Chronic Pulmonary Aspergillosis, CPA, Aspergilloma	AMPHOTERICIN B, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02440009	A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis	Phase 2/3	191		Allergic Bronchopulmonary Aspergillosis	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02273661	Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).	Phase 2	174		Allergic Bronchopulmonary Aspergillosis	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov
NCT04227483	Deflazacort Vs. Prednisolone in Acute-stage ABPA	Phase 2/3	150		Allergic Bronchopulmonary Aspergillosis	DEFLAZACORT, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT05444946	Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome	Not applicable	104		Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis	ITRACONAZOLE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01321827	Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis	Phase 2/3	100		Allergic Bronchopulmonary Aspergillosis	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT05129033	A Prospective Study on Optimizing Treatment for ABPA	Not applicable	100		Allergic Bronchopulmonary Aspergillosis	ITRACONAZOLE, OMALIZUMAB, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00974766	Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis	Phase 2/3	92		Allergic Bronchopulmonary Aspergillosis	PREDNISOLONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dupilumab 300 mg Q2W vs Placebo: deaths from any cause	1 of 35	1 of 27	62	NCT04442269	Trial comparisons
Dupilumab 300 mg Q2W vs Placebo: serious adverse events	3 of 35	5 of 27	62	NCT04442269	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42845221	DERIVED	1	PubMed
38387646	DERIVED	1	PubMed
34764182	DERIVED	1	PubMed
33027187	DERIVED	1	PubMed
30561849	DERIVED	1	PubMed
30049743	DERIVED	1	PubMed
29331473	DERIVED	1	PubMed
26585431	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015243

GET https://conductscience.org/api/diseases/v1/MONDO_0015243/drugs

API reference For AI assistants